GlaxoSmithKline: EU committee backs new inhaler for COPD.
(CercleFinance.com) - GlaxoSmithKline and US partner Innoviva said on Friday that their inhaler has received the go-ahead from European regulators for the treatment of chronic obstructive pulmonary disease (COPD).
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for their product as a maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Trelegy Ellipta is a combination of an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2-adrenergic agonist, delivered once daily in GSK's Ellipta dry powder inhaler.
A final decision by the European Commission is due by the end of 2017.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for their product as a maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Trelegy Ellipta is a combination of an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2-adrenergic agonist, delivered once daily in GSK's Ellipta dry powder inhaler.
A final decision by the European Commission is due by the end of 2017.
Copyright (c) 2017 CercleFinance.com. All rights reserved.